Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug

2025-09-29 09:00:32

(MENAFN- AsiaNet News)

Dogwood Therapeutics, Inc. (DWTX) shares surged 50% in the pre-market session on Monday after the company announced that it has secured a license to develop Serpin Pharma's intravenous formulation of SP16 to manage cancer-related pain (CRP).

The royalty-free, global license will enable the company to develop SP16 for a broad range of chemotherapy-induced neuropathy symptoms as well.

In return, Sepin Pharma and its designated affiliates will get 7.31% of the company's common stock, on a fully diluted basis. This includes 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, it said.

Get updates to this developing story <directly on Stocktwits.

MENAFN29092025007385015968ID1110124689

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.